Summary
Alumis: Is Envudeucitinib The 'Real Deal?' We Should Find Out Soon
Alumis receives a renewed Buy rating, driven by upcoming data catalysts for lead candidate envudeucitinib in psoriasis and SLE. Phase 3 data for envudeucitinib showed strong efficacy and safety, though not outright superiority versus competitors, and twice-daily dosing is a minor drawback. Upcoming 2026 catalysts include long-term psoriasis data, NDA submission, and pivotal SLE data, all critical for valuation and acquisition potential.
Alumis: Oral Psoriasis Med Can Win Approval, Challenge Big Pharma In Major Markets
Alumis Inc. is upgraded to Buy, reversing a prior Sell, based on strong Phase 3 envudeucitinib psoriasis data and pipeline potential. Envudeucitinib demonstrated efficacy comparable to JNJ's newly approved Icotyde, with 74% PASI 75 and 59% sPGA 0/1 at week 16. ALMS targets NDA submission for envudeucitinib in 2H 2026, with additional data in psoriatic arthritis and SLE expected in 2026.
ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies
Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong skin clearance.
Alumis Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 415 | $1,656.27 | $11,105.4 | $9,449.13 | 570.51% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 13 | $286.39 | $348.98 | $62.59 | 21.85% |
 Farallon Capital Farallon Capital Management LLC | 11,000 | $242,330 | $296,451.1 | $54,121.1 | 22.33% |
| BG Bart Gancher Intech Investment Management LLC | 29,591 | $133,170.96 | $794,370.39 | $661,199.43 | 496.5% |
 John H. Burbank III Passport Capital LLC | 2.01M | $30.69M | $54.03M | $23.33M | 76.01% |
Alumis Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JS Janani Sundararajan Chardan Capital | 3,748.13 | $100,000 | $108,114.69 | $8,114.69 | 8.11% |
Alumis Inc. (ALMS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Alumis Inc. ever had a stock split?
Alumis Inc. Profile
| Biotechnology Industry | Healthcare Sector | Martin Babler CEO | NASDAQ (NGS) Exchange | 022307102 CUSIP |
| US Country | 223 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Alumis Inc. is a clinical-stage biopharmaceutical entity dedicated to forging new paths in the treatment of autoimmune disorders. This commitment is underpinned by its focus on the research, development, and eventual commercialization of innovative medicinal solutions aimed at addressing a variety of autoimmune diseases. Marking a significant milestone in its journey, the company transitioned to Alumis Inc. in January 2022, evolving from its former identity as Esker Therapeutics, Inc. This rebranding reflects a broader strategic vision as it progresses with its clinical endeavors. Established in 2021, Alumis Inc. anchors its operations in South San Francisco, California, positioning itself in the vibrant hub of biotechnological innovation.
Products and Services
Within its innovative portfolio, Alumis Inc. is advancing the development of specialized therapeutic solutions, primarily focusing on:
- ESK-001: This prime candidate emerges as an allosteric tyrosine kinase 2 (TYK2) inhibitor, meticulously designed to combat a trio of conditions—plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis. ESK-001 represents a novel approach in the immunological modulation of these diverse yet impactful autoimmune disorders, highlighting Alumis Inc.’s commitment to addressing complex medical needs through scientific ingenuity.
- A-005: Tailored for the profound challenges of neuroinflammatory and neurodegenerative diseases, A-005 leverages its distinction as a central nervous system-penetrant allosteric TYK2 inhibitor. This strategic focus on neurology underscores a deep reconnaissance into unlocking new therapeutic avenues for conditions traditionally constrained by limited treatment options, illuminating Alumis Inc.'s pioneering spirit in neuroscientific exploration.
